Pharma Industry

India's pharmaceutical industry is stepping into 2026, marking the beginning of a critical five-year period to build the required ecosystem to establish itself as an innovation hub in its bid to become a USD 500 billion sector by 2047, amid near-term challenges of tariff fluctuations and global trade realignments. The predominantly generic medicines-driven domestic drug industry, which has grown from USD 3 billion to USD 60 billion in size over the past 25 years, is shifting towards innovation in next-generation drugs. At the same time, it will also seek to capitalise on the opportunity to capture drugs worth over USD 300 billion that are set to lose exclusivity over the next seven years. "Today, Indian pharma stands at a defining moment and the next 25 years will be shaped by innovation, quality, and access," Indian Pharmaceutical Alliance Secretary General Sudarshan Jain said. The innovation agenda has gained notable momentum among the domestic players, he noted. "From 2026 onwa

DGFT's floor prices on select bulk drugs aim to curb Chinese dumping, support PLI-backed manufacturers and lift domestic offtake, though capped medicine prices may limit cost pass-through

With Mounjaro gaining ground, launch comes just three months before Novo loses patent for semaglutide

The approval marks a major win for Sun Pharma in its patent dispute with Danish drugmaker Novo Nordisk, the company that manufactures weight loss drug Ozempic

Exporters like Sun Pharma, Dr Reddy's may see 7-8% revenue lift, yet margins pressured by high raw material import costs

Following the Chhindwara cough syrup tragedy, a CDSCO committee has advised consultations to phase out high-risk solvents in oral formulations

The DCC has asked the Centre to address gaps in drug-standard enforcement, write to states on non-uniform norms and improve testing and regulatory infrastructure highlighted under the SHRESTH index

Zydus Lifesciences Ltd on Wednesday said it has entered into an exclusive licensing and commercialisation agreement with RK Pharma Inc of the US for a new sterile injectable oncology supportive care product for the US market. Under the terms of this agreement, RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA (new drug application) submission and commercialisation of the product in the US, the company said in a regulatory filing. The product is expected to be filed in 2026 and will provide a formulation that is intended to provide reduced dosing error and enhanced compliance of healthcare professionals, it added. "This partnership reinforces our commitment to delivering high-quality, affordable medicines and improving patient care," Zydus Lifesciences Managing Director Sharvil Patel said. RK Pharma Founder and Executive Chairman Ravishanker Kovi said, "Our collaboration with Zydus, a company with robust regulatory expertise and

Industry representatives argue that global acceptance of Indian Pharmacopoeia could significantly reduce export costs and make Indian drugs more affordable to developing nations

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

The initial public offer of Sudeep Pharma Ltd received 5.09 times subscription on the second day of bidding on Monday. The IPO received bids for 5,37,83,650 shares against 1,05,64,926 shares on offer, according to NSE data. The category for non-institutional investors fetched 12 times subscription, while the quota for Retail Individual Investors (RIIs) got subscribed 4.96 times. The Qualified Institutional Buyers (QIBs) portion received 13 per cent subscription. Sudeep Pharma on Thursday said it has mobilised Rs 268.5 crore from anchor investors. The Rs 895 crore initial public offering (IPO) will conclude on Tuesday. The price band has been fixed at Rs 563-593 per equity share. The IPO has a fresh issue of equity shares worth Rs 95 crore and an offer-for-sale of nearly 1.35 crore equity shares, aggregating to Rs 800 crore, by the promoters. Proceeds from the fresh issue to the tune of Rs 75.81 crore will be used for capital expenditure towards the procurement of machinery for it

The regulator told states not to demand USFDA or EU approvals in tenders after complaints that Indian-made devices were being sidelined

Mankind Pharma has entered a licensing agreement with Actimed Therapeutics to develop and commercialise cachexia treatment products across India and neighbouring South Asian markets

Despite this, the CDMO segment remained Akums' key growth driver, contributing Rs 804 crore, or 79 per cent of its total revenue

Servier India has tied up with MedGenome and Reliance-backed Strand Life Sciences to offer low-cost IDH1 and IDH2 biomarker testing for rare cancers like AML and CCA across India

Emcure Pharmaceuticals on Tuesday reported a 25 per cent increase in profit after tax to Rs 251 crore in the September quarter, aided by strong sales performance across domestic and export markets. The drug firm posted a profit after tax (PAT) of Rs 202 crore during the July-September quarter of the last fiscal. Revenue from operations rose to Rs 2,270 crore in the second quarter as against Rs 2,002 crore in the year-ago period, Emcure Pharmaceuticals said in a statement. "We continue to augment our portfolio in all our focus markets through in-licensing and in-house developments. Novo Nordisk partnership positions us well in the fast-growing obesity segment and gives us an early entry, enabling us to shape the market, Emcure Pharmaceuticals Chief Executive Officer and Managing Director Satish Mehta said. The company remains focused on delivering strong growth along with margin improvement in all key businesses, he added. Shares of the company were trading 3.90 per cent down at Rs

2.4 mg injectable Poviztra to mark next phase of weight-loss rollout

The one-year grace period for MSME drug manufacturers to comply with revised Schedule M norms has ended, with the CDSCO instructing state regulators to initiate inspections & action against violators

Weight-loss drug rakes in ₹333 cr in cumulative sales since launch in March this year, leaving rival Wegovy behind

The drugmaker's revenue fell 9% in Q2FY26 on below-par CDMO performance; company says it faced inconsistent funding in H1FY26